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Metastatic breast cancer (MBC) remains an incurable disease. The aims of treatment
include tumour shrinkage, symptom control, delay of disease progression and
prolongation of survival while maintaining an acceptable quality of life. In the
last decade, a decline in mortality has been observed. Combination chemotherapy
generally provides some survival advantage over single-agent chemotherapy.Taxanes
and antimetabolites are among the most effective agents, providing a balance
between efficacy and tolerability. Increasing numbers of patients are receiving
adjuvant anthracycline and taxane therapy. In these patients, treatment options
include cytotoxic agents not used in adjuvant treatment, re-challenge with
anthracycline and taxanes, or new targeted agents such as pertuzumab, lapatinib
or bevacizumab. Biology of the disease at cell level plays a major role in treatment
choice. Key points in the intracellular signal transduction pathways relevant for cell
proliferation, apoptosis and the angiogenesis/metastasis process, represent possible
targets for new target-specific agents. Tailored therapies are a step forward in
improving patients’ prognosis.
© 2007 Elsevier Ltd. All rights reserved.
1. Introduction
Breast cancer is the most commonly diagnosed cancer
in women worldwide with 1.15 million cases diagnosed
according to Globocan 2002 data, and is the most
prevalent cancer in women, with 4.4 million surviving
up to 5 years following diagnosis 1. Data show that
approximately 50% of new cases and breast cancer
deaths occur in developing countries, underlining the
fact that the disease is a global concern 1. Fortunately, in
most countries a decline in mortality has been observed
despite the continuous increase in diagnosis of new
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cases. In fact, the increased incidence demonstrates that
primary prevention of breast cancer, at least for the
moment, is not feasible, while the increased efficacy
of secondary prevention (screening) and more active
treatments have led to both earlier detection and an
improved cure rate. The majority of breast cancer
patients are cured in the adjuvant setting. However,
even in the case of metastatic breast cancer (MBC),
survival prolongation has been achieved, with a fraction
of patients surviving beyond 5 years.
2. MBC: Disease characteristics and desirable
treatment endpoints
In spite of a screening programme, early diagnosis
and the efficacy of adjuvant post-operative therapies,
a significant proportion of breast cancer patients still
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develop distant metastases. Until recently, the proportion
of patients in Italy who developedmetastatic disease was
25−30%; however, according to the most recent data from
the Modena Cancer Registry, this proportion has now
fallen to less than 20% 2. Thus, in developed countries,
probably more than 80% of all breast cancer patients
are effectively cured and will never develop metastases.
According to the database of University Hospital,
Modena, Italy, metastatic spread is diagnosed at a mean
age of 66 years, by which time a significant proportion of
patients already suffer with co-morbidities. The majority
of patients (70−80%) who develop metastases have failed
adjuvant chemotherapy, usually on cyclophosphamide,
methotrexate and 5-fluorouracil (CMF), but more re-
cently, patients have increasingly been treated with
anthracycline and taxanes. The median recurrence-
free survival time from primary tumour diagnosis
to metastatic spread is approximately 3 years. Most
metastatic patients have visceral metastases (50−60%)
and/or bone metastases (65−75%), and approximately
20% have human epidermal growth factor receptor-2
(HER2)-overexpressed disease.
The desirable treatment endpoints for patients with
MBC are prolongation of survival, achieving symptomatic
control, tumour shrinkage and maintaining or improving
quality of life (QoL). Unfortunately, cure is unattainable
for the vast majority of these patients. Therefore, in order
to maintain an optimal QoL, it is important to balance the
efficacy of treatment with its toxicity.
Traditionally, hormone receptor status has been the
main characteristic used in clinical practice for deciding
how to best treat MBC.Tumours with a positive oestrogen
receptor (ER) or progesterone receptor (PR) status are
usually treated with endocrine therapy, whereas those
patients with a negative hormone receptor status
will only respond to chemotherapy or trastuzumab.
Other important characteristics include the disease-
free interval (DFI), the rate of tumour growth (slow-
growing tumours are more often treated with endocrine
therapy, whereas more aggressive tumours are treated
using chemotherapy), the site and extent of metastatic
spread in the viscerae, and the performance status
of the patient. Finally, all patients, even those who
have received several lines of endocrine therapy, will
eventually require chemotherapy as the tumour becomes
hormone refractory.
3. Management of MBC
In attempting to establish which type of chemotherapy
provides maximum benefit for endocrine-resistant pa-
tients with MBC, it is useful to review the data available
from different periods of chemotherapy development.
3.1. The anthracycline era
The survival of patients with MBC has improved
over recent decades. This is due to several factors
including stage migration and more favourable biological
parameters. However, the availability of new active
agents is a key factor in explaining the improved
outcome 3,4.
During the anthracycline era, quality of response to
first-line chemotherapy was clearly the best predictor
of long-term outcome. In patients receiving first-
line treatment with 5-fluorouracil, doxorubicin and
cyclophosphamide (FAC) or similar combinations, only
those patients who achieved a complete clinical response
(CR) had a more prolonged survival, while those patients
who achieved a partial response, stabilisation of disease
or no response attained a poorer and shorter survival
irrespective of any salvage treatment 5.
3.2. The taxane era
More recently, taxanes have been developed as very
active agents for treating breast cancer. However,
randomised clinical trials have failed to consistently
prove the superiority of first-line regimens that included
this novel class of agents. The activity of taxanes
as salvage treatment, the difficulty in developing
anthracycline plus taxane-based combinations and the
limited statistical power of many trials may explain the
disappointing results obtained. However, a meta-analysis
recently published by the Cochrane Collaboration clearly
indicated that, in general, taxane-containing regimens
improved overall survival, time to progression and overall
response versus non-taxane regimens in patients with
MBC 6.
4. Quality of response as a surrogate endpoint for
survival
Quality of response to first-line chemotherapy was
clearly a valid predictor of long-term outcome when very
few effective salvage agents were available. As objective
responses and, in particular, complete responses were
more frequently observed with combination regimens,
combination chemotherapy was commonly considered
superior to single-agent regimens. This assumption
was challenged when effective salvage cytotoxic agents
became available. In fact, as discussed above, some trials
failed to show clear superiority of combination regimens
over sequential administration of single agents 7,8. Again,
however, two meta-analyses that included data from
randomised clinical trials 9 and from a single institution
database 10 confirmed that combination chemotherapy is
better than single-agent treatment and that response to
first-line chemotherapy is the best predictor of survival
irrespective of second-, third- or fourth-line treatment.
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Table 1 – Treatment options according to prior adjuvant therapy in the ‘old’ scenario
Treatment Prior adjuvant treatment
No anthracycline Anthracycline Anthracycline + taxanes
1st-line Anthracycline-based regimens Anthracycline + taxanes Taxanes ± antimetabolite 1 Antimetabolite 1
2nd-line Taxanes ± antimetabolite 1 Antimetabolite 1 Antimetabolite 2 Antimetabolite 2
3rd-line Antimetabolite 2 Antimetabolite 2
Other commonly used drugs: vinorelbine, liposomal doxorubicin, or cyclophosphamide, methotrexate and 5-fluorouracil.
Re-challenge can be tested when treatment-free interval >1 year.
5. The ‘old’ treatment scenario
All these data, however, must be interpreted with caution
as most patients who participated in the trials studied in
these meta-analyses belonged to the ‘old’ scenario where
adjuvant treatments rarely included anthracyclines.
Thus, in case of relapse, several therapeutic options
were still available, from anthracycline-based regimens
to taxanes and antimetabolites (Table 1).
For example, after anthracycline failure a survival
advantage could be attained by combining an an-
timetabolite with a taxane. Two randomised trials have
shown the superiority of combination therapy. Docetaxel
plus capecitabine was found to be superior to single-
agent docetaxel, while gemcitabine plus paclitaxel was
found to be superior to single-agent paclitaxel 11,12.
More recently, a randomised trial has shown that
the combinations of gemcitabine plus docetaxel and
capecitabine plus docetaxel are equally effective, al-
though gemcitabine plus docetaxel is more tolerable 13.
In summary, in the pre-anthracycline era, combination
therapy – mainly CMF – proved more active than single-
agent therapy; in the anthracycline era, anthracycline-
containing combinations proved more effective than
non-anthracycline-containing combinations. More re-
cently, the availability of taxanes, either upfront or as
a salvage treatment, has induced a further survival
benefit. It should be noted that even in the taxane
era, combination chemotherapy provided a limited
but significant survival advantage over single-agent
chemotherapy. A major advance, however, has been the
development of trastuzumab, a monoclonal antibody
against the HER2 receptor. Two randomised trials
have shown that, in patients with HER2-overexpressing
tumours, chemotherapy plus trastuzumab is significantly
superior to chemotherapy alone in all treatment
outcomes (response rate, progression-free survival and
overall survival) 14,15. Interestingly, in both trials, the
combination of chemotherapy with trastuzumab pro-
duced better survival despite a significant proportion
of patients randomised to chemotherapy alone having
received trastuzumab upon progression.This observation
is consistent with the preclinical data that demonstrated
the synergistic interaction of several chemotherapeutic
agents with trastuzumab in HER2-overexpressing cell
lines 16.
The patients included in all of these trials, however,
belonged to the ‘old’ scenario. Some of these patients
had never received adjuvant chemotherapy, CMF was still
a common adjuvant regimen, only a small proportion
of patients had failed on an adjuvant anthracycline,
and even fewer had failed on adjuvant therapy with an
anthracycline plus a taxane.
6. The ‘new’ treatment scenario: biology drives
choice
Making treatment decisions in today’s clinical practice is
like trying to hit a moving target. Factors such as tumour
biological profile, the site and extent of metastasis, the
type of prior adjuvant treatments and, of course, patient
characteristics and needs all require consideration.There
is a need to discriminate between ER/PR-positive and
-negative tumours, HER2-positive and -negative tumours,
and to ascertain whether there is locoregional relapse
or metastatic spread, where metastases are present,
and whether they are visceral, bone or soft-tissue
metastases.
In practice, patients with MBC are usually categorised
according to low or moderate/high risk for death sooner
rather than later. Patients at low risk have ER-positive
cancer, HER2 overexpression (which predicts the efficacy
of trastuzumab) and a long disease-free survival time
(DFS) after primary surgery, with limited metastatic
spread in bone or soft tissue. High-risk patients, on
the other hand, have ER-negative, HER2-negative cancer,
a shorter DFS and extensive metastatic spread, with
visceral metastases and involvement of vital organs.
Thus, in today’s ‘new’ scenario, tumour biology plays
a major role in treatment choice. More patients are
diagnosed with a limited tumour burden and the
majority of patients have already failed on adjuvant
anthracyclines or anthracycline plus taxane regimens.
Are single-agent antimetabolites the only treatment
option for this majority group of patients (Table 2)?
If this is indeed true, then it should be recognised that
this situation is similar to that of patient treatment in
the second- or third-line setting of the ‘old’ scenario:
i.e., there are no data showing any survival advantage
for a single agent in managing these patients. Therefore,
the treatment of patients who have failed on adjuvant
therapy with an anthracycline and a taxane represents
an increasing and unmet clinical need. On the other
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Table 2 – Treatment options according to prior adjuvant therapy in the ‘new’ scenario
Treatment Prior adjuvant treatment
No anthracycline Anthracycline Anthracycline + taxanes
1st-line Anthracycline-based regimens Anthracycline + taxanes Taxanes ± antimetabolite 1 Antimetabolite 1
2nd-line Taxanes ± antimetabolite 1 Antimetabolite 1 Antimetabolite 2 Antimetabolite 2
3rd-line Antimetabolite 2 Antimetabolite 2
Trastuzumab for IHC 3+ or FISH-positive patients. Other commonly used drugs: vinorelbine, liposomal doxorubicin, or
cyclophosphamide, methotrexate and 5-fluorouracil. Re-challenge can be tested when treatment-free interval >1 year.
hand, we know that the interval between primary tu-
mour and development of metastases (DFI) is an impor-
tant prognostic and predictive parameter. Furthermore,
several agents have shown activity after anthracyclines
and taxanes. Options in this ‘new’ scenario include
cytotoxic agents not used in the adjuvant setting such
as capecitabine, vinorelbine, gemcitabine, vinflunine or
ixabepilone, re-challenge with the same drugs already
used as adjuvant treatment (anthracyclines, taxanes,
aromatase inhibitors, trastuzumab), or new targeted
agents such as pertuzumab, lapatinib or bevacizumab.
Another important observation is that today more pa-
tients are diagnosed with limited tumour burden because
of increasingly sophisticated diagnostic procedures such
as magnetic resonance imaging and positron emission
tomography. As a consequence, palliation is also no
longer the main goal of treatment for metastatic disease
as most patients have a good performance status and are
asymptomatic.
7. QoL predicts survival
Treatment must be tailored to individual patient needs,
from survival prolongation to symptomatic control and
maintenance of QoL. Increasingly, there is a need to
discuss the importance of QoL with patients when
predicting survival in MBC. QoL scores after disease
relapse that demonstrate a better mood, appetite and
physical well-being are a significant prognostic indicator
of improved survival 17. This follows on from the
observation by Greer et al. nearly 30 years ago that
patients with a ‘fighting spirit’ or emphatic denial of the
disease had a more positive outcome than those who
stoically accepted the situation 18.
There is also a requirement to manage the patient’s
needs and expectations, and to discuss treatment
options with him or her after adjuvant anthracycline
and taxane failure. With respect to treatment decision-
making, patients mostly prefer to share control with their
doctor rather than a relative 19. This is important in that
patient expectations have been shown to differ, often
more positively, from those of healthcare professionals.
For instance, a survey by Slevin 19 of 100 patients
with solid tumours indicated that they were willing
to accept more aggressive therapies associated with
a 1% chance of cure versus a 50% chance chosen
by healthy controls, or the 10−15% chance of cure
chosen by healthcare professionals. Cancer patients
found a 12-month prolongation of life derived from
aggressive treatment acceptable versus 24−60 months
of prolongation in healthy control participants, and
12−24 months for healthcare professionals. Patients were
also more willing to accept aggressive therapies than
healthy controls or healthcare professionals with respect
to symptomatic relief 19. Thus, greater effort should be
made to involve patients in decision-making and when
treatment is being selected.
8. Oligometastatic disease: A curable disease?
For a small fraction of patients with MBC who have
low-burden and chemosensitive disease there may be
a possibility of cure. Low-burden disease is not easy to
define but, in general, it involves several instances of
locoregional relapse, and three or fewer sites of lung
metastases, liver metastases or brain metastases. It is
also associated with limited bone metastases.
A survey by Greenberg et al. demonstrated the
prognostic relevance of tumour burden in patients with
recurrent metastatic disease 5. Data showed that the
probability of achieving a CR to first-line chemotherapy
was higher for patients who had a limited burden
of chemotherapy. More importantly, the proportion of
patients who maintained a CR after 5 years or more was
directly dependent on the tumour burden at diagnosis
of metastatic spread. To illustrate this, 464 of the
1581 patients in this survey had one metastatic site and
of these 25% had a CR, whereas of the 288 patients
with four or more metastatic sites only 8% achieved a
CR. More than 1 in 5 of the patients who achieved a
CR to first-line chemotherapy and who had a limited
tumour burden at diagnosis still maintained a CR after
5 years 5. Thus, for a small proportion of patients, long-
term remission with standard chemotherapy regimens
is a reality. However, the better prognosis of low burden
MBC can be due to earlier diagnosis or simply to lead-
time bias, and there may be no difference in OS between
early- and late-diagnosed MBC.
ejc supplements 5, no. 1 (2007) 11–16 15
Oligometastatic disease, defined as low-burden dis-
ease, is amenable to local treatment capable of control-
ling detectable tumour sites. Several treatments have
shown potential in curing oligometastatic disease 20.
These include surgery, radiofrequency ablation, gamma-
knife, vertebroplasty or orthopaedic surgery.
There are some long-term survivors following surgical
resection of apparently solitary cerebral, hepatic and
pulmonary metastases 21−25. However, in most studies
the patients had received systemic therapy after
surgical resection. Prognostic factors associated with
better prognosis after surgery include good performance
status, long disease-free interval, complete resection of
metastatic tumour, number of metastatic nodules (<3)
and size of lesions (<2 cm). Rivera et al. performed a
retrospective analysis on 259 patients with stage IV
breast cancer without evidence of disease (NED) after
surgical resection of recurrent metastatic lesions. These
patients were treated with chemotherapy and compared
with a historical control group of 62 patients who had
not received chemotherapy following surgery. The study
showed an improvement in OS and DFS for patients with
stage IV-NED treated with doxorubicin-based adjuvant
chemotherapy 26. This finding is in accordance with the
belief that most of these patients had micrometastases
at the time of their first recurrence. Newer techniques,
such as a circulating tumour cell assay or reverse
transcription-polymerase chain reaction assay to detect
micrometastases early,might be able to distinguish those
patients who would benefit from systemic therapy in
addition to local therapy from those who would not
benefit.
9. Chemosensitive disease
Patients with chemosensitive disease can be identified
on the basis of their clinical characteristics and
tumour biological profile. These are patients who
have had no prior adjuvant chemotherapy, or a long
DFI following adjuvant chemotherapy. Patients with
HER2-positive tumours can be successfully treated
with trastuzumab, while among triple-negative tumours
there are highly chemoresistant as well as highly
chemosensitive tumours. In future, the possibility may
exist to identify specific markers of chemosensitivity,
such as overexpression of TOPOIIa, low t protein level
and perhaps specific gene signatures 27,28.
There are reports in the literature showing that a
mutimodal approach, including chemotherapy and local
therapies, may improve long-term survival in patients
with limited visceral metastases. In these instances,
prolonged median overall survival can be achieved
leading to 35−80% and 22−50% of patients with lung
and liver metastases, respectively, surviving beyond
5 years 29−32.
10. Conclusion
At presentation, the majority of patients with MBC do
not require palliation, and indeed this is not the goal
of first-line treatment for most patients. The primary
aim is prolongation of survival, which can be achieved
using chemotherapy both as first-line treatment and
following anthracycline failure. Inevitably, the need for
palliation increases with disease progression. Taxanes
and antimetabolites such as gemcitabine are among the
most effective agents to be used in combination therapy,
thereby providing an optimal balance between efficacy
and tolerability. Combining certain chemotherapeutic
and targeted agents can also achieve added benefit
through synergistic efficacy. Finally, it must be remem-
bered that cure may be a realistic goal of treatment for
a small subset of patients with oligometastases and that
biology plays a major role in treatment choice. Tailored
therapies will likely represent a further step in improving
the prognosis of these patients.
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